(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
24 June 2021 (24.06.2021)

WIPO | PCT

(10) International Publication Number
WO 2021/123294 A1

(51) International Patent Classification:
C07D 471/04 (2006.01) *A61P 25/28* (2006.01)
A61K 31/437 (2006.01)

(21) International Application Number:
PCT/EP2020/087201

(22) International Filing Date:
18 December 2020 (18.12.2020)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

19383138.5	18 December 2019 (18.12.2019)	EP
20197523.2	22 September 2020 (22.09.2020)	EP
20203022.7	21 October 2020 (21.10.2020)	EP

(71) Applicant: **JANSSEN PHARMACEUTICA NV** [BE/BE]; Turnhoutseweg 30, 2340 Beerse (BE).

(72) Inventors: **BARTOLOMÉ-NEBREDA, José Manuel**; Janssen-Cilag, S.A., Edificio Johnson & Johnson Paseo de las Doce Estrellas, 5-7, 5° planta, Campo de las Naciones, 28042 Madrid (ES). **BUIJNSTERS, Petrus Jacobus Johannes Antonius**; Janssen Pharmaceutica NV Turnhoutseweg 30, 2340 Beerse (BE). **DE LUCAS OLIVARES, Ana Isabel**; Janssen-Cilag, S.A., Edificio Johnson & Johnson, Paseo de las Doce Estrellas, 5-7, 5° planta, Campo de las Naciones, 28042 Madrid (ES). **LEENAERTS, Joseph Elisabeth**; Janssen Pharmaceutica NV Turnhoutseweg 30, 2340 Beerse (BE). **MARTINEZ LAMENCA, Carolina**; Janssen Pharmaceutica NV Turnhoutseweg 30, 2340 Beerse (BE). **OEHLRICH, Daniel**; Janssen Pharmaceutica NV Turnhoutseweg 30, 2340 Beerse (BE). **TRABANCO-SUÁREZ, Andrés, Avelino**; Janssen-Cilag, S.A., Edificio Johnson & Johnson, Paseo de las Doce Estrellas, 5-7, 5° planta, Campo de las Naciones, 28042 Madrid (ES). **VAN ROOSBROECK, Yves Emiel M**; Janssen Pharmaceutica NV Turnhoutseweg 30, 2340 Beerse (BE). **VELTER, Adriana Ingrid**; Janssen Pharmaceutica NV Turnhoutseweg 30, 2340 Beerse (BE).

(74) Agent: **GARCIA PRIETO, Maria**; Johnson & Johnson Patent Law Department Turnhoutseweg 30, 2340 Beerse (BE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*

WO 2021/123294 A1

(54) Title: OGA INHIBITOR COMPOUNDS

(57) Abstract: The present invention relates to O-GlcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which inhibition of OGA is beneficial, such as tauopathies, in particular Alzheimer's disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by a tau pathology, in particular amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C9ORF72 mutations.